FRATES JAMES M sold $350K of AMLX
FRATES JAMES M (Chief Financial Officer) sold 10,810 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.36 ($32.27–$33.23, $0.35M total) across 2 trades on 2026-09-10.
How this was made
The 30-second read
Why it matters
The CFO's discretionary sale of roughly $350K may prompt short‑term scrutiny but is unlikely to alter long‑term fundamentals.
Market read
Primary insider filing with modest monetary value; limited trading relevance.
What to watch
CFO may be diversifying holdings; no 10b5‑1 plan indicates discretionary decision.
Background
Amylyx Pharmaceuticals (AMLX) is a biotech focused on neurodegenerative disease therapies.
Ticker impact
Chief Financial Officer sold 10,810 shares for $349,821 on 2026-09-10, reducing his stake to 233,625 shares.
Possible short‑term dip of 1‑2% as market digests the sale.
Sale size is modest relative to market cap, but CFO insider sales often attract attention; no 10b5‑1 plan suggests discretionary timing.
Market effects
Limited impact on biotech sector; similar insider sales are common.
No regional effect.
Minimal.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- OfficerFRATES JAMES M
Chief Financial Officer of Amylyx Pharmaceuticals.
